Subject(s)
Carcinoma, Renal Cell/therapy , Interferon-alpha/administration & dosage , Interleukin-2/administration & dosage , Kidney Neoplasms/therapy , Carcinoma, Renal Cell/immunology , Female , Humans , Injections, Subcutaneous , Interferon-alpha/toxicity , Interleukin-2/toxicity , Kidney Neoplasms/immunology , Male , Middle Aged , Neoplasm Metastasis , Time FactorsABSTRACT
The occurrence of an accessory liver is extremely rare and usually has no clinical significance. This malformation may harbor the same pathologic processes present in the anatomically normal liver.
Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Liver/abnormalities , Carcinoma, Hepatocellular/complications , Humans , Liver Neoplasms/complications , Male , Middle AgedABSTRACT
Authors refer results obtained in 24 cases of primary NHL of gastrointestinal tract. These cases were observed in the period 1981-1990. All cases can be included as primary extranodal lymphomas satisfying criteria of the literature. Sixty-six per cent (16/24) had a gastric localization half cases were centrocytic-centroblastic lymphomas followed by immunoblastic, centroblastic, follicular centrocytic-centroblastic and lymphocytic-well-differentiated. In intestinal localisation (34% of cases), the most represented was lymphocytic poor-differentiated, followed by mixed centrocytic lymphoma. Therapeutic strategy was: surgery in all patients followed by chemotherapy (CHOP 14/24) or by radiotherapy plus chemotherapy (8/24). Surgery alone was adopted in 2 out 24 patients. Patients who received radiotherapy plus chemotherapy had a sandwich treatment (CVP = 4/8, CHOP = 4/8) consisting of splint course of 3 cycles followed by radiotherapy and completed with other 3 drugs cycles. Sixteen out 24 patients were valuable (4 patients were lost during the follow-up due to problems other than the disease; 4 patients are still under treatment). In the 16 valuable patients we had a complete remission (CR) with a median free-disease survival of 82 months (range: 12-116 months) by means of the primary treatment. Four out 16 patients relapsed. In these patients the free-disease survival was range 8-108 months. All patients reached a second CR by means of chemotherapy (CCNU + VIP16) or radiotherapy. No cases of second tumor insorgence was observed.
Subject(s)
Gastrointestinal Neoplasms/pathology , Lymphoma, Non-Hodgkin/pathology , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Gastrointestinal Neoplasms/epidemiology , Gastrointestinal Neoplasms/therapy , Humans , Lymphoma, Non-Hodgkin/epidemiology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Postoperative Care , Prednisone/administration & dosage , Remission Induction , Vincristine/administration & dosageSubject(s)
Child Behavior , Child Development , Infant, Newborn , Infant, Postmature , Delivery, Obstetric , Humans , LearningABSTRACT
The effects of chronic alcohol consumption on plasma branched chain amino acids and alanine concentrations were evaluated, and basal blood concentrations of these amino acids were determined after chronic ethanol intake and following a withdrawal period in 30 admitted alcoholics. After ethanol intake, alcoholics showed increased branched chain amino acid concentrations; the blood alanine concentrations were depressed after the withdrawal period. To evaluate the effect of ethanol on diurnal variations of these amino acids in the blood, a group of these patients underwent two isocaloric diets with and without wine. The diet with alcohol induced a sustained increase of branched chain amino acids persisting even after the postprandial phase with a decrease of alanine as compared to the diet without.
